Neurosense Taps Phasev’s Ml Tech For Phase Iii Als Trial Analysis

NeuroSense and PhaseV are collaborating to use causal machine learning for clinical trial analysis and optimization of NeuroSense’s ALS therapy. The therapy, PrimeC, is an oral combination of two FDA-approved drugs and has received orphan drug designation. The Phase III trial is expected to begin in the next few months.